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he second edition of Neurotransmitter continues our mission to provide you with a glimpse
of the breadth of work being performed across our member institutions — George Washington Institute for Neurosciences (GWIN), part of the GW School of Medicine and Health
Sciences (SMHS); the George Washington University Hospital’s Neurological Institute;
and the GW Medical Faculty Associates.
This issue describes many of our investigations into neurological disorders at the molecular-cellular level. One of the newest members of the SMHS research community, Robert H. Miller, Ph.D., senior associate dean for research, Vivian Gill Distinguished Research
Professor, and professor of anatomy and regenerative biology at SMHS, has devoted decades to understanding the myelin coating of nerve cells in the brain. His studies have led
to the identification of drugs that enhance the repair of myelin and suppress the immune
system injury produced in models of the devastating human disease, multiple sclerosis.
Anthony-Samuel LaMantia, Ph.D., professor of pharmacology and physiology at SMHS
and director of GWIN, and colleagues take novel approaches that link animal and human
studies to understand dysphagia — an under-appreciated, devastating disorder that prevents normal eating and swallowing.
Moving to patient care, Veronica Slootsky, M.D., RESD ’15, assistant professor of psychiatry and behavioral sciences at SMHS, discusses multiple treatment options for severe
depression using state-of-the-art brain stimulation methods (see also special section on
stimulation procedures for severe epilepsy). Jonathan Sherman, M.D., assistant professor
of neurological surgery at SMHS, reports on treatment for the glioblastoma brain tumor.
Despite decades of attempts to improve treatment, the tumor remains lethal. Sherman
describes his work to alleviate the suffering of patients. In addition to these major features, we have added brief descriptions on a few of the many activities between SMHS and
its clinical partners. Our investigators have provided insights into two aspects of autism.
One may explain why boys are more likely to suffer from autism, while the other describes
how nerve cells move during brain development, and how this protein may also contribute to autism. Other stories feature neurologists and scientists who care for patients with
a spectrum of diseases that affect nerve and muscle. Two of the members of the neuroscience institute, Mohamad Z. Koubeissi, M.D., FAAN, FANA, associate professor of neurology and director of the SMHS Epilepsy Center, and Donald Shields, M.D., Ph.D., FACS,
assistant professor of neurological surgery at SMHS, were recently featured in a National
Geographic documentary series, “Breakthrough,” for their work in the treatment of intractable epilepsy. They have proposed a novel surgical approach that uses deep brain stimulation to provide low-frequency stimulation to deep brain structures to treat the seizures.
The preliminary results in the two patients treated thus far are encouraging.
As emphasized in the introduction to the first Neurotransmitter (visit smhs.gwu.edu/
neurotransmitter to view a copy), a common theme among the features is to advance
care for individuals challenged with brain disorders, and the driving force is collaboration. The more brains working together, the better. We hope Neurotransmitter will stimulate your neurons.
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THE NEUROSCIENCES INSTITUTE (NI) at The George Washington University Hospital is a premier neurological center. Patients come for
comprehensive interdisciplinary care by the Institute’s internationally recognized team of experts. The team treats patients for a wide range
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WORDS TO THE WORLD

“...we will have greater
opportunity to
educate and improve
knowledge ...”
MOHAMAD KOUBEISSI, M.D.

The George Washington University (GW) Epilepsy Center’s “Epilepsy Grand Rounds,”
a monthly seminar series that began in January 2013, has found a new home with epilepsy.com, the Epilepsy Foundation’s website.
“Thanks to our partnership with epilepsy.com, this series will now be visible to hundreds of thousands of physicians, health care providers, and laypersons from all over
the world,” said Mohamad Koubeissi, M.D., director of the GW Epilepsy Center and
associate professor of neurology at the GW School of Medicine and Health Sciences.
“With this exposure, we will have greater opportunity to educate and improve knowledge, competence, and clinical performance for larger numbers of attendees.”
The series appears on epilepsy.com/professionals, a branch of the site that houses a
forum for innovative voices in the field. The GW lectures are also live-streamed, which
allows attendees to pose questions in real time, and are archived for future viewing.
The series provides continuing medical education for participating physicians, as well.
Epilepsy.com is a primary resource for those living with epilepsy; their caregivers;
and experts in the treatment, care, and research of the neurological condition. Visit
smhs.gwu.edu/epilepsy/ for more information.

RORA PROTEIN A FACTOR IN AUTISM SEX BIAS
Sifting through the potential reasons behind sex bias in autism, Valerie Hu,
Ph.D., professor of biochemistry and molecular medicine at the GW School
of Medicine and Health Sciences, has uncovered an important factor:
the sex-dependent difference in the protein levels of the gene retinoic
acid–related orphan receptor-alpha (RORA), a nuclear hormone receptor that functions as a transcription factor.
“According to the Centers for Disease Control and Prevention,
males are nearly four times as likely as females to have autism, but
the reason for this sex bias is still a mystery,” explained Hu. “Our research suggests that deficiencies in RORA expression in the brain
may have a greater impact on males, which may contribute to the
known sex bias in autism in several ways.”
Looking at genetically identical mouse models, Hu and her research
team found a twofold higher level of RORA expression in the frontal cortex of female mice than in male mice. They also determined that the correlation between RORA and target gene expression in the cortex was higher
in male mice than female mice. On the human side, the team found a strong
positive correlation between the levels of RORA and aromatase protein — an enzyme
that converts male to female hormones — in the frontal cortex in males and females
without autism spectrum disorder, and in males with autism. That correlation didn’t appear in females with autism, suggesting that they may have compensatory mechanisms
for regulating RORA target genes to offset RORA deficiency.
“Overall, this study suggests that RORA deficiency may have a greater impact on
males, not only because males have lower baseline levels of RORA in the brain to start
with, but also because the expression of autism-associated genes may be more highly
correlated with the lower expression of RORA in males,” said Hu. “This provides yet
another plausible explanation for sex differences in autism susceptibility.”
Hu’s study, “Investigation of sex differences in the expression of RORA and its transcriptional targets in the brain as a potential contributor to the sex bias in autism,” appeared in the May 2015 edition of Molecular Autism.
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EVOLVING BRAINS: GENOMES,
CONNECTOMES, AND DIVERSITY
A rapt audience of neuroscientists and students ringed
the tables filling the George Washington University’s
(GW) Marvin Center for the fifth annual Neuroscience
Symposium, titled “Evolving Brains: Genomes, Connectomes, and Diversity,” in the spring of 2015.
Presenters at the GW Institute for Neuroscience
(GWIN)–sponsored symposium included students and faculty members from GW’s School of Medicine and Health
Sciences (SMHS) and Children’s National Health System
(Children’s National), as well as three renowned keynote
speakers: Yoav Gilad, Ph.D., professor of human genetics
at the University of Chicago; David Van Essen, Ph.D., Alumni Endowed Professor of Anatomy and Neurobiology at
Washington University; and Jon Kaas, Ph.D., Distinguished
Centennial Professor of Psychology, associate professor of
cell and developmental biology, and professor of radiology and radiological sciences at Vanderbilt University.
“[Our keynote speakers] really provided us with a diverse, but nevertheless coherent, view of how to think
about the brain, the underlying genomic constraints of
building it, the way that it may be connected to ensure
diverse forms of behavior, and finally, how throughout
evolution, these final patterns of connectivity to ensure
optimal function have emerged,” said Anthony-Samuel
LaMantia, Ph.D., professor of pharmacology and physiology at SMHS and director of GWIN.

GW SMHS faculty and student topics included the
genetics and biology of cognitive disorders and noninvasive neuroimaging of brain organization, among
others. This year’s symposium also featured poster presentations by students from both GW and neighboring
institutions, such as George Mason University, American
University, and the National Institutes of Health.
Although a date has not yet been set, plans are already underway for the 2016 event.

PERSONALITIES PEPPER PRESENTATIONS AT
NEUROSCIENCE CONFERENCE

FRANÇOIS BOLLER, M.D.,
Ph.D., professor of neurology
at GW’s School of Medicine
and Health Sciences,
and past president of the
International Society for the
History of the Neurosciences

The personalities at the heart of the lectures at the 20th annual International Society for
the History of the Neurosciences (ISHN) meeting spanned centuries, encompassing the
worlds of music, art, literature, and pop culture. Gathered under the umbrella of neuroscience, the characters — some revolutionary, some infamous — not only contributed
to the art and science of medicine, but also provided great fodder for the lecturers and
participants gathered at the George Washington University (GW) in early June.
“The schedule was stocked with a lot of interesting things,” said Henry Kaminski,
M.D., chair and professor of neurology at the GW School of Medicine and Health Sciences, who chaired the introductory session of this year’s ISHN conference.
Topics and accompanying personalities included mechanical neuroscience in operetta — a short, light form of opera popularized by composer Jacques Offenbach and
lyricist-composer duo W.S. Gilbert and Arthur Sullivan; color theory; depictions of multiple sclerosis in literature; and the storied tale of physician Walter Freeman, prolific
performer and enthusiastic promoter of lobotomies.
The weeklong event, sponsored by the GW departments of history and neurology,
also featured a trio of symposia, poster presentations, and a keynote speech by Daniel
Drachman, M.D., who discussed the history of myasthenia gravis.
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A PIECE OF THE PUZZLE
GW School of Medicine and Health Sciences (SMHS) researchers have fit another piece into the complex puzzle
of a genetic developmental disorder that leads to behavioral diseases.
Anthony-Samuel LaMantia, Ph.D., professor of pharmacology and physiology at SMHS and director of the GW
Institute for Neuroscience (GWIN), along with Thomas Maynard, Ph.D., associate research professor
of pharmacology and physiology at SMHS, and
post-doctoral fellow Daniel Meechan, Ph.D., has
spent the last nine years investigating how behavioral disorders such as autism, attention deficit
hyperactivity disorder, and schizophrenia emerge
during early brain development. In their most recent
study, the research team showed how autism-related genetic lesions interfere with cellular and molecular mechanisms that ensure the development of interneurons.
Interneurons, a critical type of cortical neuron, appeared in the correct number outside the cortex but
were not able to move properly into the cortex, where
they normally help control cortical circuit activity. The

reason, according to the research, was a diminished expression of activity of a key regulatory pathway for migration — the Cxcr4 cytokine receptor. Earlier, LaMantia
had determined that another critical neuron, the projection neuron, was not generated in appropriate numbers
during development in a 22q11.2 Deletion Syndrome
mouse model.
“This gives us two pieces of the puzzle for this
genetic developmental disorder,” said LaMantia. “These two pieces tell us that in very early
development, those with 22q11.2 Deletion Syndrome do not make enough cells in one case,
and do not put the other cells in the right place.
This occurs not because of some degenerative
change, but because the mechanisms that make these
cells and put them in the right place during the first step
of development have gone awry due to mutation.”
The study, “Cxcr4 regulation of interneuron migration is disrupted in 22q11.2 deletion syndrome,” appears in the Proceedings of the National Academy of
Sciences journal.

GW RESEARCHERS SEEK HIGHER RESEARCH
STANDARDS FOR MYASTHENIA GRAVIS

“The conference was
a pivotal moment in
myasthenia gravis
research. We no
longer want to simply
use medications
developed for other
diseases and adapt
them for myasthenia
gravis patients.”
HENRY KAMINSKI, M.D.
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For those suffering from myasthenia gravis, a rare, debilitating autoimmune disorder,
effective medication is lacking, owing to a high failure rate of potential drug compounds. Soon, however, patients may have recourse; Linda Kusner, Ph.D., associate research professor of pharmacology and physiology at the GW School of Medicine and
Health Sciences (SMHS), is taking concrete steps toward a solution.
In September 2014, Kusner organized a two-day workshop, “Standards for Preclinical Efficacy Evaluations for Myasthenia Gravis,” at the National Institute of Neurological
Disorders and Stroke (NINDS), with support from NINDS, SMHS, and the Myasthenia
Gravis Foundation. The goal: tackling the failure rate by looking at deficiencies in preclinical assessments of possible therapies.
“The conference was a pivotal moment in myasthenia gravis research,” said Henry
Kaminski, M.D., Meta Amalia Neumann Professor, chair of the Department of Neurology, and conference participant. “We no longer want to simply use medications developed for other diseases and adapt them for myasthenia gravis patients. This conference focused specifically on drug development for myasthenia gravis.”
Myasthenia gravis experts discussed raising research standards and updating consensus guidelines for experimental methods, outcome assessments, and statistical requirements to be used worldwide. Experts also identified important variables to control, such as the phenotype of laboratory animals.
A follow-up meeting, part of the Association of British Neurologists-hosted “Myasthenia Gravis & Related Disorders” conference, will take place in Oxford, England in
January 2016. Both Kusner and Kaminski will assist with event organization.
In August 2015, Experimental Neurology published a special edition dedicated to
summaries of the September 2014 conference as well as reviews of other topics related
to therapy evaluations for myasthenia gravis.
For more information visit www.gwdocs.com/neurology/myasthenia-gravis-center.

SPOTTING THE SOURCE OF STRESS
Stress is the bane of the
modern world. Bills, demands at work, even laundry can trigger pressure
sensors that leave the
heartiest among us full
of anguish and anxiety.
Stress, particularly in the
animal kingdom, on the
other hand, developed
as a life-saving mechanism. The fight or flight
instinct keeps us on our
game when faced with
challenges, and it keeps
prey animals on their toes
when sensing danger.
A team of researchers,
led by Joshua Corbin,
Ph.D., principal investigator in the Center for Neuroscience Research at Children’s National Health System, and associate professor of
pediatrics and of pharmacology and physiology at GW’s School of Medicine and Health
Sciences, recently uncovered a gene common in a range of species that plays an essential role in the developing nervous system, particularly in specifying neurons required
for the brain’s stress system. The investigators identified a gene known as Dbx1, which
is only active during the early embryonic stages, yet has long-lasting effects after its
limited window of activity has closed.
This discovery enables science to take a big step toward understanding gene processes and how they affect behavior. The research, published in the April 2015 edition
of the journal Neuron, shows that while Dbx1 is only expressed for a brief period during brain development, it unleashes a cascade of events that impact the expression of
other genes critical for proper brain development.
Mice models reveal that this embryonic gene is critical for establishment of the
brain’s stress axis; removal of the gene before birth virtually eliminates the specific
aspects of the animals’ stress response later in life. When investigators genetically
removed Dbx1 from the mice, they were surprised to discover just how selective the
effects of a lack of Dbx1 were to both developmental programs and behavior. Without the gene, stimulus, such as the scent of a natural predator, failed to trigger the
appropriate response.
“The Dbx1 gene has a very specific function to developing and building circuits and
behavior,” explained Corbin. With the removal of the Dbx1 gene, “basically the mice
don’t have the normal stress response because they lack this gene. The circuitry of the
stress system was not really there.
“Now we have a piece of information that sheds light on the genetic programs that
drive innate behavior circuit formation,” Corbin said. “We now understand much better how this system is established from early stages of brain development. How that
development unfolds has been, up to now, poorly understood — a kind of black box.”
The findings, he said, open the door to understanding how similar evolutionarily
conserved brain structures are formed in humans. The long-term impact of specific
genetic mutations may affect these developmental processes, areas of investigation
that would demand further study.

Stress, particularly in
the animal kingdom,
developed as a lifesaving mechanism.
The fight or flight
instinct keeps us on
our game when faced
with challenges, and
it keeps prey animals
on their toes when
sensing danger.

A team of
researchers, led
by Joshua Corbin,
Ph.D., recently
uncovered a gene
common in a range of
species that plays an
essential role in the
developing nervous
system, particularly
in specifying neurons
required for the
brain’s stress system.
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Illuminating
Pediatric Dysphagia
GENETIC MOUSE MODEL TAKES CENTER STAGE AS RESEARCHERS
INVESTIGATE FEEDING AND SWALLOWING DISORDER
CAROLINE TRENT-GURBUZ
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“Can you imagine,” said Anthony-Samuel LaMantia,
Ph.D., director of the GW Institute for Neuroscience
and professor of pharmacology and
physiology at the GW School of
Medicine and Health Sciences (SMHS),
“you’re an infant, and one of the key
behaviors you have to learn is to ingest
food. Someone comes at you with food,
and it hurts!” That pain, a product of
pediatric dysphagia, is at the heart
of what LaMantia and his team are
working to solve. With a five-year,
three-pronged plan and a $6.2 million
program project grant (PPG) from the
National Institute of Child Health and
Human Development, PPG director
LaMantia is determined to tackle the
problem where it begins: in the brain.
Act One: The Basics

Pediatric dysphagia presents as a mostly
mechanical problem; infants and children are unable to chew and swallow
and may aspirate or choke on what they
try to consume. Complications include
ear and sinus infections and dribbles of
liquid that settle in the lungs.
Today, dysphagia is treated symptomatically. There is no cure, and
researchers understand little about a
disorder that ranges from mild to severe. What researchers do know is that
it can appear in as many as one in four
children, and up to 80 percent of those
with neurodevelopmental disorders,
such as autism, have dysphagia. “This is
a real-life disease,” LaMantia said.
Dysphagia is also a tricky disease. As
LaMantia pointed out, delving deeper
into the “whys” and “hows” of a disorder
that appears in babies has limitations;
researchers and physicians would prefer
using minimally invasive techniques
with infants. The ideal solution, therefore, is an animal model.
Act Two: The Mouse Model

LaMantia has dedicated the past 15
years to DiGeorge Syndrome, or 22q11.2
Deletion Syndrome, which occurs
when a small part of chromosome 22’s
long arm is missing. The effects are
far-reaching, and patients suffer from
a medley of complications. LaMantia’s

research on DiGeorge Syndrome — and
the genetic mouse model he and his
team use — unlocked the link between
the deletion and the resulting dysphagia.
“It is remarkable how good a model
this is,” LaMantia said. “The insight
that we were initially able to get supported our basic hypothesis.”
Their hypothesis was that dysphagia emerges when fundamental
mechanisms in early brain development are disrupted, causing defects in
the neurons that become part of the
cranial nerve system. The discovery
also revealed that dysphagia develops
embryonically. With that in mind,
the researchers at SMHS and clinical
partner institution Children’s National
Health System (Children’s National) decided to use the mouse model to further
understand dysphagia.
Act Three: The Team

To best tackle the causes of dysphagia,
LaMantia and PPG associate director Sally Moody, Ph.D., professor of
anatomy and regenerative biology at
SMHS, assembled a cast of experts in
mouse genetics, bioinformatics, maternal nutrition, and neuronal functioning.
“The project was put together to try
to attack the problem, or at least analyze
the problem, from a multidisciplinary
perspective,” Moody explained. “It’s the
combination of expertise that we think
will allow us to make progress.”
Act Four: The Project

The investigation is divided into three
parts: the origin of dysphagia, the pathology, and a possible path to prevention, all of which researchers will pursue
simultaneously while informing one
another of their progress.
Part one, headed by David Mendelowitz, Ph.D., vice chair and professor of pharmacology and physiology,
with Norman Lee, Ph.D., professor of
pharmacology and physiology; Thomas
Maynard, Ph.D., associate research
professor of pharmacology and physiology; and Anastas Popratiloff, M.D.,

Ph.D., adjunct professor of anatomy and
regenerative biology, focuses on dysphagia in newborns. More specifically, the
researchers will assess any abnormalities in the neuroanatomical connections
that control the muscles an animal uses
to feed and swallow.
In part two, LaMantia, Moody, and
Lee are zeroing in on the development
of the embryonic hindbrain. In early
developmental stages, a population of
cells migrates from the hindbrain into
the periphery to make craniofacial
structures. For infants with dysphagia,
somewhere along the way the mechanisms controlling how these cells develop
into peripheral neurons and the facial
skeleton go awry. “The brain has to have
a code, and the periphery has to have a
code, and they have to match,” LaMantia
said. When they don’t match, messaging
between the two becomes garbled. A second important goal of the part-two team
is to identify the genes that are altered in
the hindbrain, which can then lead to the
motor and sensory mismatches.
The third part of the project is what
LaMantia and Moody termed the most
adventurous. Retinoic acid, a derivative
of Vitamin A, is one of the signaling
factors strongly affected by the 22q11.2
deletion. Hypothesizing that maternal
nutrition — in particular retinoic acid as
it plays a role in the development of the
hindbrain — could influence the severity of dysphagia, Maynard and Irene
Zohn, Ph.D., associate professor of
pediatrics at SMHS and a researcher at
Children’s National, are experimenting
with maternal diets.
Act Five: The Goals

Although the team is still a few years
away from the project’s conclusion, the
researchers’ goals could have longlasting consequences for dysphagia
sufferers, some of whom cope with the
disease well into adulthood.
“We’re hoping that there might be
ways of regulating [dysphagia] either
prenatally via diet or postnatally
through pharmacological therapies to
help the kids overcome this behavioral
deficit that really impacts their lives,”
Moody said.
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Getting to Glioblastoma

I

ERIC BUTTERMAN

t can start with something as severe as a speech problem or a seizure, or as subtle as a
headache — but if it turns out to be glioblastoma, it unfortunately won’t end so differently. Roughly a decade ago, the drug temozolomide added to treatment at least upped
the two-year survival rate to 25 percent, according to Jonathan Sherman, M.D., assistant
professor of neurological surgery at the George Washington University (GW) School of
Medicine and Health Sciences (SMHS) and director of surgical neuro-oncology. But like
his fellow researchers, Sherman is striving to add more than just time. He is hoping for
a true breakthrough, even teaming up with a mechanical
engineer as one of his strategies.
TREATING GLIOBLASTOMA
“These are typically middle-aged men and women who
In search of a new treatment for
glioblastoma, which typically
you may see die in a year or two after [a glioblastoma] diaffects middle-aged men and
agnosis,” he said. “We’ve seen so many good people go
women, Jonathan Sherman,
through this. We’re working on many things, and we’re
M.D., assistant professor of
driven.”
neurological surgery at the
For Sherman, an important challenge came from the
George Washington University
need to understand brain tumors from the basic science
School of Medicine and Health
perspective. It was no easy task. “That meant time on the
Sciences, is even teaming up
bench learning cell culture and how it related to treatment
with a mechanical engineer as
— it was a huge learning experience,” he said. “I began this
one of his strategies.
work studying cancer stem cells and developing a technique to more easily localize them within the tumors. I next
looked at treating these cancer stem cells in an effort to treat the entire tumor. I thought
this [area of research] could be rewarding if I collaborated with the right people to grow
my science knowledge. Studying cancer stem cells takes time and, bottom line, you need
good collaborators around you.”

Into Action
In understanding stem cells, his recent work, collaborating with SMHS faculty members
Anthony-Samuel LaMantia, Ph.D., professor of pharmacology and physiology, and Sally
Moody, Ph.D., professor of anatomy and regenerative biology, involves the study of Fox
genes in relation to tumor formation. Fox genes are a family of transcription factors, some
of which have been implicated in glioblastoma. Therefore, SMHS has been looking at how
glioblastoma tumor cells form in relation to specific Fox genes. “They play a role in gene
expression,” Sherman said, “but, the question is: Will it impact treatment? Only time will
tell.” With a differentiation model, he and his collaborators “look to further characterize
the relationship of these genes to glioblastoma formation in an effort to develop new
treatment targets.” More results will be shared in an upcoming paper.
Another project he couldn’t have predicted involved cold atmospheric plasma — and
teaming with a mechanical engineer. “I started working with Michael Keidar, Ph.D., professor of mechanical and aerospace engineering at GW’s School of Engineering and Applied Sciences, around four or five years ago. He developed a device that generates cold
atmospheric plasma from electrified helium. We partnered up to look at glioblastoma
on cell-level models,” said Sherman. “It was about understanding how this cold plasma,
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“We have to remember that it’s been a tough battle with glioblastoma for
40 years. The outcomes have been frustrating in the past for the medical
community, but that means it takes being committed to making strides and
keeping an open mind. We’re in this for a more hopeful conclusion. Patients are
depending on this work and for us to continue to be creative in our approach.”
JONATHAN SHERMAN, M.D.

through generation of oxygen free radicals, will affect
tumor death and not normal
cells. You use it on the cells,
and it treats the cells — but the
question is: How do we get it
into the brain? Our initial data
indicates that we don’t necessarily have to treat the whole
tumor and may only need to
treat part of the tumor, and
this could be a significant result in bringing this technology to clinical trial.”
The idea is, by implanting a
probe into the tumor, to treat
the tumor through a tube with
cold atmospheric plasma
treatment directly on the tumor. “There is actually a different technique where you
don’t treat tumors directly, but you treat media, and then
that media forms these free radicals,” Sherman said. “Then
the media can be placed into the resection cavity to treat residual tumor cells. We’re trying to figure out the right animal
study. It has exciting possibilities.”

From Different Angles
Sherman’s glioblastoma work is aided through specialized
imaging, which includes functional MR imaging and diffusion tensor imaging. These modalities allow researchers to
look at the relationship of the tumor to fiber tracts and eloquent cortex, where movements and speech are recorded
during the imaging. “For movement tasks, the hand, face,
and leg motor regions are identified,” he said. “For speech
tasks, the expressive [Broca’s] and receptive [Wernicke’s]
speech regions are identified. The latter information can
also be invaluable in determining which side of the brain
serves as the dominant hemisphere.”
There is also the assistance of the awake craniotomy program at the SMHS. This method involves securing the patient’s
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head and subsequent exposure of the brain. The subject
is conscious (albeit provided
with anesthesia) so that motor and speech areas can be
mapped through stimulation
with relation to the tumor. “Typically, the tumor is then resected through continuous testing
while the patient is conscious,”
Sherman explained. “The published literature [describes]
an increased degree of tumor resection with decreased
morbidity or permanent neurological deficits using awake
surgical resection.” Without
hurting the patient, the more
you can remove of the tumor,
the greater the potential to increase length of survival.
Even infrastructure improvements are on the radar, as
GW is looking to soon build one of the first intraoperative
MRIs in the area. “This technology allows the surgeon to
perform an MRI of the brain during the surgical resection to
assess for residual tumor,” Sherman said. “The literature supports the use of this technology with a statistical increase in
degree of tumor resection.”

The Fight Continues
For Sherman, he’s optimistic about having several present
and possibly future treatment options to fight against this
disease, but cautions that patience will be critical. “We have
to remember that it’s been a tough battle with glioblastoma for over 40 years,” he said. “The outcomes have been
frustrating in the past for the medical community, but that
means it takes being committed to making strides and keeping an open mind. We’re in this for a more hopeful conclusion. Patients are depending on this work and for us to continue to be creative in our approach.” For more information
visit gwdocs.com/neurosurgery.

Researchers Gain Ground in
Treating Multiple Sclerosis

R

THOMAS KOHOUT AND CAROLINE TRENT-GURBUZ

esearchers, including Robert Miller, Ph.D., senior associate dean for research, Vivian Gill
Distinguished Research Professor, and professor of anatomy and regenerative biology
at the George Washington University School
of Medicine and Health Sciences (SMHS),
have taken another step forward in tackling multiple
sclerosis (MS).
MS develops when the immune system, namely T-cells, attacks the myelin sheath, the fatty insulation that
surrounds axons; consequently,
communication between the
brain and the body is disrupted, and nerve deterioration occurs. Preventing
this neural degeneration
requires
remyelination
through new oligodendrocytes, cells that create
the myelin sheath. That’s
where Miller and his fellow researcher, Paul Tesar,
Ph.D., a professor in Case
Western Reserve’s Department of Genetics and Genome
Sciences, come in.
“Current therapies focus on
stopping immune system attacks,
slowing the progression of the disease,”
said Miller, who joined SMHS at the start of the
2014 academic year. “Our goal is not to try to stop the immune attack, because we can do that quite well. The goal is
to try to actually repair the brain itself.”
Over the years, Miller explained, there has been marked
success in the development of a number of immunosuppressant therapies that target the central nervous system
T-cells. The most effective therapies actually block T-cell
entry into the brain and spinal cord. “Those work incredibly
well,” he said. “The problem is they don’t actually regulate
the disease at all. The disease is still ongoing in the brain

and spinal cord, even though the patients feel better because they have fewer attacks.”
Contrary to conventional wisdom, the body — through
brain and spinal cord neural stem cells — is capable of
creating new neurons, as well as new oligodendrocytes.
Through screening a library of bioactive small molecules,
researchers discovered therapeutic compounds for
enhancing myelination from oligodendrocyte progenitor cells, the stem cells in
the central nervous system that are
the primary source for myelinating oligodendrocytes. From
that development, Miller and
Tesar found two drugs, miconazole and clobetasol,
that could have a significant impact on reversing
the severity of MS.
“We asked if we could
find a faster and less invasive approach by using
drugs to activate native
stem cells already in the
adult nervous system and
direct them to form new myelin,” Tesar said. “Our ultimate
goal was to enhance the body’s
ability to repair itself.”
Miconazole, the scientists discovered, functions directly as a remyelinating
drug, enabling the body to repair the protective
myelin coating over the nerves without affecting the immune system. Clobetasol, which serves as a powerful immunosuppressant, also functions as a remyelinating agent.
“While successful in vivo, we’re looking forward to continuing our research through further testing of miconazole
and clobetasol, taking the next steps to finding treatments
for MS,” Miller said.
Miller and Tesar’s report, “Drug-based modulation of
endogenous stem cells promotes functional remyelination
in vivo,” was published in the spring 2015 edition of Nature.
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Neurology begins with
the brain, but that’s
hardly the end of it.
Neurological diseases
as a whole involve the
brain, the central nervous
system, the spinal cord,
the nerve roots, and
peripheral nerves and
connect with muscles
— and there’s disease at
each of those points.

More than a million
people in the United
States are affected
by some form of
neuromuscular disease.
About 40 percent of
them are under age 18.
For more information
visit www.gwdocs.com/
neurology.

Putting Muscle
Behind Neuromuscular
Disease Research
STEVE GOLDSTEIN
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The George Washington University
has a “muscular” advantage in treating
some of the most common — as well as
rare — disorders.
According to the Muscular Dystrophy Association, more than a million
people in the United States are affected by some form of neuromuscular
disease, and about 40 percent of them
are under age 18. These diseases are
rare acquired or inherited (genetic)
conditions that affect some part of
the neuromuscular system such as
the muscles, the peripheral motor
nerves (in the arms, legs, neck, or face),
the neuromuscular junction where
the nerves and muscles meet, or the
muscle-controlling nerve cells (motor
neurons) in the spinal cord.
Diseases such as myasthenia gravis and amyotrophic lateral sclerosis
(ALS) are rare but well known due to
their devastating consequences. Far
more common conditions include
sciatica, carpal tunnel syndrome, and
other peripheral neuropathies. Within
GW’s Department of Neurology is
the Neuromuscular Disease Division,
whose highly skilled clinicians care for
patients with peripheral nerve diseases,
motor neuron disorders, and muscle and
neuromuscular transmission disorders.
“Neuromuscular experts form a
subset of neurologists,” said Henry Kaminski, M.D., Meta Amalia Neumann
Professor and chair of the Department
of Neurology at GW’s School of

Medicine and Health Sciences
(SMHS). “We’re looking at the output
of the brain and how dysfunction to
those systems leads to disease.”
A Muscular Team

The division team includes director
Perry Richardson, M.D. ’84, professor of neurology and of neurological
surgery; assistant professors of neurology Elham Bayat, M.D., RESD ’06, and
Karim Salame, M.D.; and Kaminski.
The ALS Clinic is the only one in the
Washington, D.C. metro area supported by the ALS Society. The diagnosis of
neuromuscular disorders is facilitated
by an advanced electrodiagnostic laboratory, which has received the highest
possible accreditation with exemplary
status from the American Association
of Neuromuscular and Electrodiagnostic Medicine.
“There is no other center in the
D.C. area with the breadth of expertise in neuromuscular disease, with
independent validation, coupled with
the research done in conjunction with
national organizations and the innovative translational research being done
on the GW campus,” Kaminski said.
Kaminski’s NIH-supported research has focused on myasthenia gravis. “One of the most exciting things
we did here at GW is identify in patients with myasthenia gravis a unique
expression of a protein called survivin,
which is also found in cancer cells
and helps keep them alive,” Kaminski
explained. “This protein is expressed
in the immune cells of patients, and
we think survivin is responsible for
keeping these cells alive. Since these
cells are responsible for the disease,
we’re going to develop a treatment that
eliminates the expression of the protein in these cells. So far, in animals,
it’s worked very well!”
Richardson recently completed a
study, sponsored by Pfizer, Inc., to assess the efficacy and safety of pregabalin treatment in subjects with chronic
post-traumatic peripheral neuropathic
pain. “Neuromuscular disease is in
kind of a growth spurt of use of therapeutics, especially as we define many

of them as autoimmune,” Richardson
explained. “Immune-mediated diseases
lend themselves to treatment by drugs.”
Richardson also said there may be
new treatment options on the horizon
for CIDP — Chronic Inflammatory
Demyelinating Polyneuropathy —
which has a fatality rate exceeding 10
percent. “CIDP is the disorder that
starts out looking like Guillain-Barre
syndrome [a treatable autoimmune
disease sometimes triggered by an
infection that leads the body to attack
the nerves, leading to sudden onset
of muscle weakness and pain], but it
doesn’t go away,” Richardson said.
“We’re very excited that some of the
hitherto undiagnosed neuropathies are
now attributed to CIDP and therefore
treatable. Multi-focal motor neuropathy is a cousin of that, where instead
of sensory and motor loss, there’s just
motor problems.”
ALS on Trial

Research trials for ALS, popularly
known as Lou Gehrig’s disease, are
being pursued by Bayat, director of the
ALS Clinic, who completed her neurology residency at GW, where she served
as a chief neurology resident. She
then went on to complete her clinical
neurophysiology fellowship, which also
included Electromyography (EMG)
and neuromuscular disorders, at GW.
The newest member of the division, Salame, is researching the muscle
aspect of the nerve in neuromuscular
diseases. He most recently co-authored a chapter in the new edition of
Neuromuscular Disorders in Clinical
Practice, one of the only comprehensive books in the field of neuromuscular disease, which was co-edited by
Kaminski.
Diagnostic Science

Richardson stresses that diagnostic
capability is crucial for effective treatment. “Our lab stands in two rooms
with EMG instruments, and these instruments measure biological signals to
interrogate nerve function and muscle
function,” Richardson said. “It’s a tremendous extension of the neurological

exam because you generate a hypothesis from the history and exam and the
lab can verify the hypothesis. It detects
disease, it locates whether the problem
is coming from the limb nerve or the
spinal nerve root or the motor neuron
— or just the muscle, as a myopathy
instead of a neuropathy. And it can tell
us something about the prognosis and
whether surgery is really necessary.”
Kaminski said the lab has detected
erroneous diagnoses from tests performed elsewhere. “The lab testing
is absolutely critical for coming to an
appropriate diagnosis,” he asserted.
“We often have patients where we
have to repeat the study because the
previous tests were not done in a rigorous fashion.” He added that one of his
lab technicians has written a book on
performing electrodiagnosis.
The division also performs diagnostic muscle and skin biopsies, the best
way to diagnose peripheral neuropathies. “These are capabilities that most
community neurologists and, quite
frankly, most centers in the area do not
have,” said Kaminski.
Physical Medicine and Rehab

Richardson also cited the importance of
t”the GW Medical Faculty Associates’
relatively new Division of Physical Medicine and Rehabilitation (PM&R) created
by Kaminski. “Many of the patients we
see do not have nerve issues, but rather
muscular-skeletal issues, and PM&R is
very valuable,” said Richardson.
“We’re able to marry up patients
with the right treatment, including
medications for neuropathic pain, and
we help decide when to get surgery
for spinal root problems and when to
get injections into peripheral nerve
territory,” said Richardson. Innovative
treatments include steroids for carpal
tunnel syndrome and botulinum toxin
(Botox) for spasticity and to reduce
drooling for ALS patients.
“The value of our division,” concluded Richardson, “is we see a huge number of conditions that are common,
and we have the ability and experience
to be precise about unraveling difficult
diagnoses of conditions that are not.”
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Neuromodulation for
Treating Depression
ELECTRICAL AND MAGNETIC STIMULATION OFFER NEW WAYS TO TREAT DEPRESSION

I
“Neurons use
electricity to
communicate, and
we can modulate
that without the
use of medication.”
VERONICA SLOOTSKY, M.D.

FEELING BLUE
Depression is a disorder that affects
about 15 million people in the
United States at any one time.

SANDEEP RAVINDRAN

magine feeling constantly tired and sad, being unable to concentrate, and losing interest
in activities you previously enjoyed. These are just some of the symptoms of depression,
a disorder that affects about 15 million people in the United States at any one time.
Left untreated, depression can have severe consequences, affecting work and personal relationships, and potentially contributing to suicide. Although antidepressant medication and psychotherapy can be effective at treating depression, up to a third of patients
fail to respond even after multiple courses of medication.
There is hope for patients with treatment-resistant depression, in the form of neuromodulation, which uses electrical or magnetic stimulation to modify brain circuitry.
“Neurons use electricity to communicate, and we can modulate that without the use of
medication,” said Veronica Slootsky, M.D., RESD ’15, assistant professor of psychiatry and
behavioral sciences at the George Washington University School of Medicine and Health
Sciences (SMHS).
Some of these neuromodulatory therapies have been used for decades; others are still
experimental. With current advances in neuromodulation, these treatments provide useful alternatives for patients for whom antidepressants and psychotherapy aren’t sufficient.
“It’s nice to have another tool in our toolbox,” Slootsky said.

Neuromodulation Has Come a Long Way
Neuromodulation encompasses a wide range of techniques. Although all of them use
either electrical or magnetic stimulation to affect the brain, the precise mechanism by
which they work is still not completely understood. There are several hypotheses for how
the stimulation works: It may alter levels of signaling molecules in the brain, or cause the
release of certain hormones, or increase levels of growth factors that promote the growth
and survival of neurons.
Regardless of the specifics, some of these therapies affect the whole brain, whereas
others are used to target particular regions. “The reason that we choose these different
regions is that prior studies using functional MRI have determined that those regions are
implicated in certain disorders, such as depression,” said Slootsky.
Probably the best-known neuromodulation technique is electroconvulsive therapy
(ECT), which has been used to treat psychiatric illnesses since 1938. ECT uses electric
currents passed through the brain to trigger a brief seizure, and can quickly reverse symptoms of some mental illnesses.
Current ECT treatments use low doses of electricity in conjunction with modern anesthesia and muscle relaxants, reducing the risk of side effects such as memory loss or
confusion. “In general, it’s a very safe treatment, and for many patients it can be lifesaving,” said Slootsky.
Despite being one of the most effective and safe treatments for severe mental illnesses, ECT still has negative associations due to its early incarnations, which used high doses
of electricity and were administered without anesthesia. “This is a great, great method,
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which unfortunately suffers from a lot of stigma, so it’s really
underutilized,” Slootsky said.
ECT is very useful for treating patients with severe depression, especially those who have failed to respond to other treatments. “For patients with depression with psychotic
seizures, it can be up to 95 percent effective, which is huge,”
said Slootsky. The therapy generally provides much quicker
relief than medications, and is therefore helpful in patients
who are at acute risk of suicide or are catatonic. “For some
disorders it’s really one of the best treatments we have, and
it’s often the only treatment.”
Slootsky recalls an early experience witnessing the difference ECT can make on a severely depressed patient. Before
the treatment the patient was “minimally interactive, was cognitively very slow and dull, and had a lot of the typical symptoms of very severe depression,” she said. “After two weeks,
she was like a different person when I saw her. She was joking
around; she was smiling, interactive; she just looked much
more animated, and it was a marked difference.”

Different Ways to Stimulate Brain Circuitry
ECT is invaluable for treating severe depression, but those
with mild depression can use two other neuromodulatory
techniques that utilize much weaker electrical currents:
transcranial direct current stimulation (TDCS) and transcranial alternating current stimulation (TACS). These therapies are cheaper, safer, and easier to administer than ECT.
“These are things that people can probably do at home if
they buy the unit with a doctor’s prescription and direction,”
said Slootsky.
TDCS delivers very mild electrical currents through electrodes placed on the scalp, and can excite or reduce neuronal activity in specific brain regions. The technique is still
experimental and has not yet been FDA-approved, but has
shown promising results. TACS uses the same principle, but
with alternating current instead of direct current, and is FDAapproved for treating depression.
Slootsky is preparing a study to test the effectiveness of a
TACS technology called Alpha-Stim on women with postpartum depression. The condition is “extremely common, and
some women don’t want to take medication,” said Slootsky.
The Alpha-Stim technology consists of cellphone-sized units
with electrodes attached. “They can actually take these units
home, and the electrodes are clipped to their earlobe,” she
said. “This could be a great method for patients who have
postpartum depression and would like some treatment.”
Not all neuromodulation techniques are quite as easy to
use; some require a pacemaker-like device to be surgically
implanted in patients. One such technique is called vagal
nerve stimulation (VNS), and it uses the implanted pacemaker to deliver electrical signals to the vagus nerve. VNS
has been shown to improve mood, and the method is FDAapproved for treating chronic depression.
Another technique, called deep brain stimulation, uses
the pacemaker-like device to deliver a current to electrodes
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implanted in specific brain regions, to control excessive or
abnormal electrical activity. This method has been used
successfully in patients for whom multiple attempts at
treatment have failed. However, the technique is not yet
FDA-approved.
Some neuromodulation techniques use magnets rather
than electrodes. One of them, transcranial magnetic stimulation (TMS), uses a large electromagnetic coil placed
against the scalp to generate an electric field and stimulate
brain cells. TMS is able to target certain brain structures and
improve the symptoms of depression.
“TMS is currently FDA-approved for people who have
failed their medication for depression,” said Slootsky. Unlike ECT, TMS requires no anesthesia and has no cognitive
side effects, but it is also
not as effective for people
who have found multiple
antidepressant treatments
unsuccessful, she said.
“It’s being [thoroughly] researched right now to see
if we can make it more effective for those kinds of
patients.”
For treating severe depression, another technique, called magnetic seizure therapy, has emerged
over the last decade and
VERONICA SLOOTSKY, M.D.
a half. Magnetic seizure
therapy is similar to ECT,
but uses strong magnetic
fields instead of electricity to induce electrical currents in
the brain. It is still experimental, but appears to have the
same benefits as ECT, with fewer side effects.

“Electroconvulsive

therapy is a very
safe treatment,
and for many

patients it can
be lifesaving.”

A Bright Future
As noted, several of these neuromodulatory therapies are
currently FDA-approved for treating different types of depression, and others are still experimental but appear very
promising. SMHS is currently working on getting new ECT
and TMS machines, and Slootsky hopes to begin her AlphaStim research study in the near future. Physicians will soon
have a variety of neuromodulation tools at their disposal,
and more research will help them understand how best to
administer these therapies, Slootsky said. Further studies
will also help uncover the mechanisms behind neuromodulation.
Slootsky wants to use neuromodulation in conjunction
with other treatments to help patients with treatment-resistant depression. “We’re constantly improving psychotherapy and medication management techniques as well, and I
think that we have to use a multimodal approach, and we’re
refining everything,” said Slootsky. “So I think that the future
looks pretty bright.”

The Future Caught on Camera

F
MOHAMAD Z. KOUBEISSI
M.D., FAAN, FANA

DONALD SHIELDS, M.D., Ph.D., FACS
ASSISTANT PROFESSOR OF NEUROLOGICAL SURGERY

uturist Ray Kurzweil predicts that by the 2030s humans will have the ability to connect
their brains directly to cloud computing. Many of Kurzweil’s other bold predictions have
indeed come true, but new technologies such as brain-machine interface devices will
need to be perfected for this one to take shape. The human brain is the most complex
system in the known physical universe. Some have suggested it’s so complicated we can
never really understand it. Others believe if we can understand the mathematics that define brain function, we can
make real progress.
On a basic level, the brain functions electrically, so neurosurgeons can stimulate and modify its function with electrical current. Electromagnetic force is one of the four fundamental forces of our universe. Previous human brains,
like those of James Clerk Maxwell in the 19th century,
began to delineate the mathematics of electricity (electromagnetic fields). Based in part on these principles, Thomas
Edison subsequently designed the first electrical grid in
New York City and Albert Einstein devised the theory of
relativity. In addition, the electrical currents in the brains of
these and other scientists/engineers over the past decades
DONALD SHIELDS
were instrumental in developing electrically powered comM.D., Ph.D., FACS
puters used today to plan the trajectories of electrodes for
stimulation of the brains of human patients. Recording these results in turn helps physicians to understand how the brain works, and hopefully the mathematical equations that
govern brain function.
Recently, film crews for National Geographic filmed surgeries and subsequent epilepsy
monitoring at George Washington University Hospital in two patients who underwent
deep brain stimulation (DBS) for treatment-resistant seizure disorders. Unlike DBS for
movement disorders, this procedure is designed to stimulate deep brain structures with
low frequencies. Mohamad Z. Koubeissi, M.D., FAAN, FANA, associate professor of neurology and director of the George Washington University School of Medicine and Health
Sciences’ Epilepsy Center, reports preliminary results showed “each stimulation session
reduced the odds of seizure by 92 percent over the course of the following two days. The
patients did not know they were being stimulated and had no memory or cognitive problems during the stimulation.”
During the surgery, I also placed small recording depth electrodes in the frontal, temporal and parietal lobes in order to determine where each patient’s seizures originated.
The recording depth electrodes also allow Koubeissi to evaluate what happens to seizure
activity in these areas during and after stimulation with the DBS electrode. This technique
is considered in patients who cannot safely undergo resection of the seizure focus and
continue to have seizures despite multiple anti-epileptic medications. Each of the electrodes is placed into the brain with a minimally invasive approach, using 3-D models of
the patient’s brain to plan the procedure in advance.
National Geographic will broadcast this documentary, titled “Breakthrough,” beginning this fall, as part of a series describing innovative procedures impacting the treatment
of human disease.
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